207 related articles for article (PubMed ID: 17461857)
41. Granulocyte-macrophage colony-stimulating factor induces modest increases in plasma human immunodeficiency virus (HIV) type 1 RNA levels and CD4+ lymphocyte counts in patients with uncontrolled HIV infection.
Jacobson JM; Lederman MM; Spritzler J; Valdez H; Tebas P; Skowron G; Wang R; Jackson JB; Fox L; Landay A; Gilbert MJ; O'Neil D; Bancroft L; Al-Harthi L; Jacobson MA; Merigan TC; Glesby MJ;
J Infect Dis; 2003 Dec; 188(12):1804-14. PubMed ID: 14673758
[TBL] [Abstract][Full Text] [Related]
42. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
44. Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance.
de Mendoza C; Rodriguez C; García F; Eiros JM; Ruíz L; Caballero E; Aguilera A; Leiva P; Colomina J; Gutierrez F; del Romero J; Aguero J; Soriano V;
J Antimicrob Chemother; 2007 Apr; 59(4):698-704. PubMed ID: 17327295
[TBL] [Abstract][Full Text] [Related]
45. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
Eron JJ; Gulick RM; Bartlett JA; Merigan T; Arduino R; Kilby JM; Yangco B; Diers A; Drobnes C; DeMasi R; Greenberg M; Melby T; Raskino C; Rusnak P; Zhang Y; Spence R; Miralles GD
J Infect Dis; 2004 Mar; 189(6):1075-83. PubMed ID: 14999611
[TBL] [Abstract][Full Text] [Related]
46. Potent antiviral effect of reverset in HIV-1-infected adults following a single oral dose.
Stuyver LJ; McBrayer TR; Schürmann D; Kravec I; Beard A; Cartee L; Schinazi RF; De La Rosa A; Murphy RL; Otto MJ
Antivir Ther; 2004 Aug; 9(4):529-36. PubMed ID: 15456084
[TBL] [Abstract][Full Text] [Related]
47. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
[TBL] [Abstract][Full Text] [Related]
48. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized, placebo-controlled dose-escalating trial.
Bogner JR; Roecken M; Herrmann DB; Boerner D; Kaufmann B; Gürtler L; Plewig G; Goebel FD
Antivir Ther; 1997 Dec; 2(4):257-64. PubMed ID: 11327445
[TBL] [Abstract][Full Text] [Related]
49. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection.
Montaner J; Yeni P; Clumeck NN; Fätkenheuer G; Gatell J; Hay P; Seminari E; Peeters MP; Schöller-Gyüre M; Simonts M; Woodfall B;
Clin Infect Dis; 2008 Oct; 47(7):969-78. PubMed ID: 18764771
[TBL] [Abstract][Full Text] [Related]
50. Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial.
Suleiman J; Zingman BS; Diaz RS; Madruga JV; DeJesus E; Slim J; Mak C; Lee E; McCarthy MC; Dunkle LM; Walmsley S
J Infect Dis; 2010 Feb; 201(4):590-9. PubMed ID: 20064072
[TBL] [Abstract][Full Text] [Related]
51. Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial.
Hurwitz BE; Klaus JR; Llabre MM; Gonzalez A; Lawrence PJ; Maher KJ; Greeson JM; Baum MK; Shor-Posner G; Skyler JS; Schneiderman N
Arch Intern Med; 2007 Jan; 167(2):148-54. PubMed ID: 17242315
[TBL] [Abstract][Full Text] [Related]
52. Improvement in immune parameters and human immunodeficiency virus-1 viral response in individuals treated with 16alpha-bromoepiandrosterone (HE2000).
Reading C; Dowding C; Schramm B; Garsd A; Onizuka-Handa N; Stickney D; Frincke J
Clin Microbiol Infect; 2006 Nov; 12(11):1082-8. PubMed ID: 17002607
[TBL] [Abstract][Full Text] [Related]
53. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand.
Pitisuttithum P; Gilbert P; Gurwith M; Heyward W; Martin M; van Griensven F; Hu D; Tappero JW; Choopanya K;
J Infect Dis; 2006 Dec; 194(12):1661-71. PubMed ID: 17109337
[TBL] [Abstract][Full Text] [Related]
54. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team.
Noy A; Scadden DT; Lee J; Dezube BJ; Aboulafia D; Tulpule A; Walmsley S; Gill P
J Clin Oncol; 2005 Feb; 23(5):990-8. PubMed ID: 15598977
[TBL] [Abstract][Full Text] [Related]
55. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
[TBL] [Abstract][Full Text] [Related]
56. Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: final results of two randomized phase III trials.
Caseiro MM; Nelson M; Diaz RS; Gathe J; de Andrade Neto JL; Slim J; Solano A; Netto EM; Mak C; Shen J; Greaves W; Dunkle LM; Vilchez RA; Zeinecker J
J Infect; 2012 Oct; 65(4):326-35. PubMed ID: 22634184
[TBL] [Abstract][Full Text] [Related]
57. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
[TBL] [Abstract][Full Text] [Related]
58. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection.
Margolis DM; Mukherjee AL; Fletcher CV; Hogg E; Ogata-Arakaki D; Petersen T; Rusin D; Martinez A; Mellors JW
AIDS; 2007 Oct; 21(15):2025-32. PubMed ID: 17885292
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients.
Sangkitporn S; Shide L; Klinbuayaem V; Leenasirimakul P; Wirayutwatthana NA; Leechanachai P; Dettrairat S; Kunachiwa W; Thamlikitkul V
Southeast Asian J Trop Med Public Health; 2005 May; 36(3):704-8. PubMed ID: 16124442
[TBL] [Abstract][Full Text] [Related]
60. A randomised controlled trial of oral zinc on the immune response to tuberculosis in HIV-infected patients.
Green JA; Lewin SR; Wightman F; Lee M; Ravindran TS; Paton NI
Int J Tuberc Lung Dis; 2005 Dec; 9(12):1378-84. PubMed ID: 16466061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
